Liven Pharma Limited has reported its financial results for the year ended June 30, 2026, showing a significant loss despite improvements in certain operational metrics.
- Reporting Period: Year ended June 30, 2026 (audited)
- Sales: PKR 105.81M (-16.8% YoY)
- Gross Profit: PKR 26.65M (+48.5% YoY)
- Operating Loss: PKR 77.14M (improved from a loss of PKR 490.90M YoY)
- Loss After Tax: PKR 31.14M (improved from a loss of PKR 584.46M YoY)
- Loss per Share: PKR 0.28 (restated)
- No dividend or bonus announced.
- The main driver of the results was a reduction in cost of sales and operational expenses, leading to a notable improvement in gross profit.